CO-OPTIV-SECURIT
10.6.2019 15:07:06 CEST | Business Wire | Press release
Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has been recognized by Forrester Research as a Strong Performer in The Forrester WaveTM : Global Cybersecurity Consulting Providers, Q2 2019. The report identifies Optiv as having received the highest possible score for six criteria:
- Delivery and engagement innovation
- IP and asset-based consulting
- Technical consulting and assessment capabilities
- Cybersecurity focus
- Go-to-market strategy
- Partnership ecosystems
“Optiv’s approach to cybersecurity is aligned to new business models and centered on driving client-focused outcomes. It is designed to optimize and rationalize existing cybersecurity programs, build new integrated, end to end cybersecurity programs, and help clients transform how they are consuming and applying cybersecurity,” said Bryan Wiese, division vice president, global advisory services for Optiv.
“We believe that receiving this designation from Forrester as a Strong Performer affirms our approach to consulting for global enterprises,” continued Wiese. “Historically, the fear of external threats and vulnerabilities has often guided clients’ security initiatives. That fear has sometimes led to tactical investment, too much of a focus on technology, and siloed problem solving. At Optiv we work with clients to manage their security programs from the ‘inside-out,’ starting with risk mitigation and building from there with customized strategy, focused process definition, technology rationalization and operations optimization, ongoing measurement and communication. Our approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change by providing new consumption and outcome-based consulting services and cybersecurity solutions. Our goal is help clients strike the right balance between risk mitigation, business alignment, and cost.”
Optiv’s full suite of advisory services can be consumed alone or combined with Optiv’s integration or managed services, or Cyber-as-a-Service (CaaSTM ) platform to harden security fundamentals across six main domains:
- Risk Management and Transformation – Optiv enables clients to address risk and regulatory changes with an inside-out strategy that begins with business needs and applies strategy, technology and processes to effectively manage risk and enable cyber resilience.
- Cyber Operations – Optiv helps clients strike the right balance of people, process, technologies and delivery methods in order to elevate threat preparedness while aligning business goals and operational resilience and producing measurable outcomes at reduced operational costs.
- Cyber Digital Transformation – Optiv aligns client business needs with a security-by-design approach that employs big data analytics, IoT, cloud, orchestration and automation and additional technology innovations to connect agile processes and controls.
- Identity and Data Management – Optiv helps clients tackle identity and data sprawl and exposure with comprehensive, strategic identity and data management solutions. Enabling organizations to quickly and securely provide access to the right company assets on- and off-premise ensures trust and compliance in the business while also strengthening security by classifying, governing and protecting sensitive data.
- Threat Management – Proactively solving threat management requires a comprehensive program that includes tracking technological and regulatory changes, driving security into network design and software development lifecycles, continual threat modeling, testing and remediation, an understanding of the attack surface, and readiness exercises to practice muscle memory and robust response should an incident occur.
Please visit Optiv’s website to learn more about Optiv’s cybersecurity consulting services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005093/en/
Contact:
Brett Ater (913) 304-7683 brett.ater@optiv.com or Jason Cook (816) 701-3374 jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
